Drug intelligence / Profile preview

glatiramer acetate + n-acetylcysteine

Development stage
Preclinical
Lead developer
Teva Pharmaceutical
Modality
Small Molecules
Administration
Subcutaneous, Intravenous, Oral, Inhalation
01

Overview

Glatiramer acetate + n-acetylcysteine is an investigational drug combination studied for the treatment of relapsing-remitting multiple sclerosis. Glatiramer acetate is a synthetic immunomodulator composed of four amino acids that mimic myelin basic protein and acts as a decoy to divert immune attacks away from myelin in the central nervous system. Its mechanism involves shifting T cell populations from proinflammatory Th1 to anti-inflammatory Th2 cells and inducing regulatory T cells that suppress inflammation[1][4][6]. N-acetylcysteine (NAC) is an antioxidant and glutathione precursor with mucolytic properties and established use as an antidote for acetaminophen overdose; it also exhibits neuroprotective effects by reducing oxidative stress[5][8]. The combination has been shown in early clinical studies to be safe and well tolerated in patients with relapsing-remitting multiple sclerosis[3].

Brand names
Acetadote
Other names
glatiramer acetaten-acetylcysteineGANACacetylcysteine
02

Targets

GSH (Glutathione)MHC II (Major histocompatibility complex class II receptor)TCR-MBP(82-100) (Myelin basic protein 82-100-specific T-cell receptor)

Beyond the preview

Go deeper on glatiramer acetate + n-acetylcysteine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on glatiramer acetate + n-acetylcysteine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call